FARMINGDALE, N.Y., Sept. 18, 2012 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), a surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products worldwide for spine surgery, cranial maxillo – facial surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, today reported financial results for the fourth quarter and the fiscal year ending June 30, 2012.
Highlights for the quarter and the fiscal year include:
Q4 2012 Financial Results:
For the fourth quarter of fiscal 2012, revenues increased 41% to $5.3 million compared to $3.8 million for the three months ended June 30, 2011. BoneScalpel revenues for the quarter increased 82% to $1.7 million compared to $906,961 in the comparable quarter of fiscal 2011. SonicOne revenues increased 89% to $517,574 compared to $273,608 in the fourth quarter last year. SonaStar revenues increased 21% to $1.7 million compared to $1.4 million in the fourth quarter last year.
Gross margin increased to 58% for the fourth quarter of fiscal 2012 from 57% for the fourth quarter ended June 30, 2011. Operating expenses for the fourth fiscal quarter increased six percent primarily attributable to continued expansion of the Company's in house sales force, commissions on expanded product sales and increased advertising and depreciation expense due to increased rented/leased/no-cap units in the field. Income from continuing operations before income taxes for the quarter was $337,042 compared to a loss from continuing operations before income taxes of $440,303 in the fourth quarter of 2011.
The financial results for the fourth quarter included net income from discontinued operations of $201,124, or $0.03 per fully diluted share – adjusted for taxes – primarily related to the sale of the Company's Laboratory and Forensic Safety Products business.
For the fourth quarter of fiscal year 2012, the Company reported net income of $444,813, or $0.03 per diluted share, compared to a net loss of $1.45 million, or $(0.21) per diluted share, in the fourth quarter of fiscal 2011.
Full year 2012 Financial Results:
Net sales increased 27% to $15.7 million for the full year ended June 30, 2012 from $12.4 million in the full year ended June 30, 2011. BoneScalpel revenues for the full year increased 92% to $4.8 million compared to $2.5 million in the prior year. SonicOne revenues increased 17% to $1.3 million compared to $1.1 million in fiscal year 2011. SonaStar revenues increased 44% to $5.9 million compared to $4.1 million in fiscal year 2011.
Gross margin increased to 59% for the full year ended June 30, 2012 from 57% for the comparable full year fiscal 2011. Operating expenses for the fiscal year increased nine percent primarily attributable to continued expansion of the Company's in house sales force, commissions on expanded product sales and increased advertising and depreciation expense due to increased rented/leased/no-cap units in the field. For the fiscal year the Company reported a net loss from continuing operations before income taxes of $608,765 compared to a net loss from continuing operations before income taxes of $2.1 million in fiscal year 2011.
The financial results for the full year included net income from discontinued operations of $975,090, or $0.14 per fully diluted share – adjusted for taxes – primarily related to the sale of the Company's Laboratory and Forensic Safety Products business.
For the full year of fiscal year 2012, the Company reported a net income of $366,325, or $0.05 per diluted share, compared to a net loss of $3.5 million, or $(0.50) per diluted share, in full fiscal year 2011.
Michael A. McManus Jr., President and Chief Executive Officer of Misonix, commented, "We are very pleased with the results of the quarter and the fiscal year. Our strategic goal has been to transition Misonix to be a focused surgical device company - and we have succeeded in achieving that goal. Going forward we have three main goals: continue to successfully place instruments throughout the surgical community worldwide; substantially grow recurring revenues through the sale of disposables; and continue to expand our worldwide distribution system.
"In that regard, we continue to gain traction in placing instruments in the market, both domestically and internationally. We achieved solid double-digit sales growth in our BoneScalpel, SonicOne and SonaStar product lines for the fourth quarter and the fiscal year. For fiscal the year U.S. sales increased 12% while international sales increased 58% as our expanding distribution channel throughout the world becomes more fully engaged in the sales process. We are particularly pleased with the 548% sales increase in Asia, primarily driven by our Korean distributor and the 49% increase in European sales, largely driven by our new eastern European distributors. In addition, Canada and Mexico, as well as South America and the Middle East contributed strong double-digit sales increases. This bodes well for the coming years."
"Our products are gaining wider acceptance as more surgical professionals throughout the world become aware of the effectiveness and the efficiencies of our products," continued Mr. McManus. "We believe that our leading-edge instruments provide surgeons the ability to spare surrounding tissue and minimize nerve-end vessel damage, while executing intricate and delicate procedures that can provide better patient outcomes, improved quality of life, and generate cost efficiencies across the patient's treatment continuum. These are strong attributes that will serve us well in successfully selling our instruments worldwide."
Mr. McManus concluded, "At the end of fiscal year 2012 the financial underpinnings of the Company are strong. We have a solid balance sheet with $6.3 million in cash and equivalents and zero long-term debt. While we are still in the early stages of operating as a pure play surgical devices provider, we are beginning to post measurable results that indicate success in executing our strategic plan. We are excited about the opportunities ahead."
Michael A. McManus Jr., President and Chief Executive Officer, and Richard Zaremba, Senior Vice President and Chief Financial Officer, will host a conference call Tuesday, September 18, 2012 at 4:30 pm ET to discuss the Company's fourth quarter and year-end results.
Shareholders and other interested parties can access the conference call by dialing (877) 317-6789 or (412) 317-6789 or can listen via a live Internet webcast, which is available in the Investor Relations section of the Company's website at www.misonix.com.
A teleconference replay of the call will be available for three days at (877) 344-7529 or (412) 317-0088, confirmation # 10018380. A webcast replay will be available in the Investor Relations section of the Company's website at www.misonix.com for 30 days.
Misonix, Inc. designs, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.
With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10 K, subsequent Quarterly Reports on Form 10 Q and Current Reports on Form 8 K. The Company disclaims any obligation to update its forward looking relationships.
Investor Relations Contact:Richard Zaremba
Joe Diaz, Lytham Partners631 694 9555
602 889 firstname.lastname@example.org
MISONIX, INC. And Subsidiaries
Consolidated Statements of Operations
UnauditedThree Months EndedTwelve Months EndedJune 30,June 30,2012
$12,373,029Cost of goods sold
3,885,784General and administrative expenses
4,499,521Research and development expenses
1,431,627Total operating expenses
9,816,932Operating income (loss) from continuing operations
(2,730,549)Total other income
689,878Income (loss) from continuing operations before income taxes
(2,040,671)Income tax expense (benefit)
64,216Net income (loss) from continuing operations
(2,104,887)Discontinued operations:Net income (loss) from discontinued operations, net of income tax expense(benefit) of $(185,336), $0, $(89,236) and $0
(1,429,359)Gain from sale of discontinued operations, net of income tax expense of $0, $0, $284,337 and $0
-Net income (loss) from discontinued operations
(1,429,359)Net income (loss)
($3,534,246)Net income (loss) per share from continuing operations-Basic
($0.30)Net income (loss) per share from discontinued operations-Basic
(0.20)Net income (loss) per share-Basic
($0.50)Net income (loss) per share from continuing operations-Diluted
($0.30)Net income (loss) per share from discontinued operations-Diluted
(0.20)Net income (loss) per share-Diluted
($0.50)Weighted average common shares-basic
7,001,370Weighted average common shares-diluted
MISONIX, INC. And Subsidiaries Consolidated Balance SheetsUnauditedJune 30, 2012June 30, 2011AssetsCurrent Assets: Cash and cash equivalents$6,273,015$6,881,093 Accounts receivable, less allowancefor doubtful accounts of $155,739 and$115,739, respectively3,158,0842,085,972 Inventories, net4,380,8413,130,207 Prepaid expenses and other current assets306,691374,472 Note receivable198,117210,000 Current assets of discontinued operations-857,095Total current assets14,316,74813,538,839Property, plant and equipment, net891,822969,336Goodwill1,701,0941,701,094Intangible and other assets1,403,1732,127,194Assets of discontinued operations-21,859Total assets$18,312,837$18,358,322Liabilities and stockholders' equityCurrent liabilities: Accounts payable$
,110,694 Accrued expenses and other current liabilities1,074,9321,969,078 Liabilities of discontinued operations-225,864Total current liabilities2,582,6273,305,636Deferred income117,147161,360Deferred lease liability22,99614,043Total liabilities2,722,7703,481,039Commitments and contingenciesStockholders' equity: Capital stock, $0.01 par value - shares authorized 20,000,000; 7,082,920 and 7,079,170 issued and 7,005,360 and 7,001,370 shares outstanding, respectively
70,82970,792 Additional paid-in capital26,132,95125,787,960 Accumulated deficit(10,202,720)(10,569,045) Treasury stock, at cost, 77,560 and 77,800 shares, respectively(410,993)(412,424)Total stockholders' equity15,590,06714,877,283Total liabilities and stockholders' equity$18,312,837$18,358,322
|SOURCE Misonix, Inc.|
Copyright©2012 PR Newswire.
All rights reserved